[Vaccination against Hepatitis B: 20 years later]

Area of Science:

• Hepatology
• Immunology
• Public Health

Context:

• Hepatitis B vaccination programs initiated in 1984 have been in place for over two decades.
• The disease landscape and vaccination strategies have evolved, utilizing plasma-derived and recombinant DNA vaccines.
• Significant reductions in acute and chronic Hepatitis B infections, infant mortality, and hepatocellular carcinoma incidence have been observed.

Purpose:

• To evaluate the long-term impact and effectiveness of Hepatitis B vaccination.
• To assess changes in Hepatitis B virus (HBV) epidemiology and vaccine efficacy over 20 years.
• To review vaccination strategies for specific populations and vaccine safety.

Summary:

• Childhood vaccination provides protection for up to 20 years, with approximately 25% reduction in key disease metrics.
• Hepatitis B surface gene mutants in HBV-positive children increased from 7.8% to 23.1% over 15 years post-vaccination, but do not impede control efforts.
• Optimized vaccination schedules for premature infants and considerations for elderly non-response have been addressed.
• The Hepatitis B vaccine is confirmed as one of the safest available globally.

Impact:

• Demonstrates the substantial public health success of Hepatitis B vaccination in reducing disease burden and mortality.
• Highlights the continued need for surveillance of HBV mutants and adaptation of vaccination strategies.
• Reinforces the safety and efficacy profile of the Hepatitis B vaccine, supporting its ongoing use in global immunization programs.